v3.24.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Medicare Advantage22 %15 %21 %17 %
Medicare20 %37 %24 %35 %
*Less than 10%.

Accounts Receivable, Net
 September 30, 2024December 31, 2023
Medicare23 %42 %
Medicare Advantage22 %16 %
*Less than 10%.
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue:
Commercial$6,779 $6,090 $22,314 $17,789 
Government2,633 4,955 10,276 13,570 
Client(1)2,981 2,319 9,175 6,999 
Other(2)114 52 221 425 
Total revenue$12,507 $13,416 $41,986 $38,783 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2024September 30, 2023
Warrants to purchase common stock325,330 409,108 
Common stock options576,151 1,004,855 
Restricted stock units1,810,468 1,568,112 
Employee stock purchase plan12,570 12,542 
Total2,724,519 2,994,617